NRx Pharmaceuticals announced that the company posted a new shareholder update letter on its website that highlights potential implications of the company’s recent announcement of a Data Sharing Agreement to gain access to the patient level, anonymized, data from a “major Ketamine study in France.” The company says the key points include: Potential NDA filing for NRX-100 in 2024; Breakthrough Therapy Designation previously granted; Data support NMDA as a more potent target in Bipolar Depression than Major Depressive Disorder; Review of other published evidence for ketamine-like effect with NRX-101; Considerable laboratory evidence supporting a ketamine like effect with DCS; MR Spectroscopy showed comparable effect of DCS and Ketamine on brain glutamate levels – a key biomarker in Bipolar Disorder.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NRXP:
- NRx Pharmaceuticals signs data sharing agreement for ketamine treatment
- NRx Pharmaceuticals announces agreement with LifeSci Associates
- NRx Pharmaceuticals announces data on in vitro activity of NRX-101
- NRx Pharmaceuticals announces submission of IND application for NRX-101
- NRx Pharmaceuticals to purchase 3M shares of preferred stock at 40c per share